跳转至内容
Merck
CN
所有图片(4)

文件

安全信息

SAB4504499

Sigma-Aldrich

Anti-phospho-p53 (pSer15) antibody produced in rabbit

affinity isolated antibody

登录查看公司和协议定价

别名:
Anti-BCC7, Anti-BMFS5, Anti-LFS1, Anti-P53, Anti-TRP53
UNSPSC代码:
12352203
NACRES:
NA.41

生物来源

rabbit

质量水平

偶联物

unconjugated

抗体形式

affinity isolated antibody

抗体产品类型

primary antibodies

克隆

polyclonal

形式

buffered aqueous solution

分子量

antigen 43 kDa

种属反应性

human, rat, mouse

浓度

~1 mg/mL

技术

ELISA: 1:10000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000

NCBI登记号

UniProt登记号

运输

wet ice

储存温度

−20°C

靶向翻译后修饰

phosphorylation (pSer15)

基因信息

human ... TP53(7157)

一般描述

TP53 (tumor protein p53) gene is located on human chromosome 17p13.1. This is a tumor-suppressor gene.

免疫原

The antiserum was produced against synthesized peptide derived from human p53 around the phosphorylation site of Ser15.

Immunogen Range: 1-50

生化/生理作用

TP53 (tumor protein p53) gene is required for the DNA-damage checkpoint.This protein controls cell cycle, senescence and apoptosis upon oncogene activation, stress and DNA damage. Mutation in TP53 results in breast cancer.

特点和优势

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

外形

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

常规特殊物品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Assessing TP53 status in human tumours to evaluate clinical outcome.
Soussi T and Beroud C
Nature Reviews. Cancer, 1(3), 233-233 (2001)
Wip1 phosphatase: between p53 and MAPK kinases pathways.
Goloudina AR, et al.
Oncotarget, 7(21), 31563-31571 (2016)
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G, et al.
Oncotarget, 7(22), 32731-32753 (2016)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门